Cole M P, Jones C T, Todd I D
Br J Cancer. 1971 Jun;25(2):270-5. doi: 10.1038/bjc.1971.33.
An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.The particular advantage of this drug is the low incidence of troublesome side effects.
本文描述了抗雌激素药物IC146474用于晚期或复发性乳腺癌的初步临床试验。46例患者接受了治疗,其中10例有良好反应。这与使用雌激素和雄激素时的情况相当。这种药物的特别优势在于不良副作用的发生率较低。